Traders should note the ex-dividend date of July 24 and the due bill period (July 21-23) for the special dividend. The reverse split will adjust the stock price upward by 50x. After the merger closes, the ticker will change to YARW. Monitor for any last-minute conditions to the merger closing.
Price Chart
Executive Summary
VYNE Therapeutics filed an 8-K announcing a 1-for-50 reverse stock split and a $17.3 million special cash dividend ($0.40242/share) in connection with its pending merger with Yarrow Bioscience. The merger is expected to close on or about July 24, 2026, with the combined company trading as YARW starting July 27. This filing provides final mechanics for the reverse split and dividend, which are procedural steps to complete the merger.
Key Facts
- Reverse stock split at 1-for-50, reducing outstanding shares from ~33.4M to ~0.7M.
- Special cash dividend of $17.3 million aggregate, or $0.40242 per share, payable to holders of record as of July 22, 2026.
- Ex-dividend date for the cash dividend is expected to be July 24, 2026, with a due bill period from July 21 through July 23.
- Merger closing expected on or about July 24, 2026; combined company to trade as YARW on Nasdaq starting July 27, 2026.
- Post-merger combined company shares: ~2.7M basic, ~33.6M fully diluted, ~28.6M excluding equity plans.
- Stockholders approved increase in authorized common stock from 150M to 300M shares in connection with the merger.
Financial Impact
Special cash dividend of $17.3 million aggregate, approximately $0.40242 per share, to be paid to stockholders and warrant holders of record as of July 22, 2026.
Risk Factors
- Merger may not close if conditions are not satisfied or waived.
- Reverse split and dividend may cause short-term price volatility around ex-dividend date.
- Post-merger combined company faces clinical-stage development risks for Yarrow's YB-101 and VYNE's InhiBET platform.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-085235 |
| Document: tm2620874d1_ex99-1.htm | 0001104659-26-085235 |
| Document: 0001104659-26-085235-index-headers.html | 0001104659-26-085235 |
| Document: 0001104659-26-085235-index.html | 0001104659-26-085235 |
| Document: 0001104659-26-085235.txt | 0001104659-26-085235 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 19d ago | SC 13G | — | awaiting T+20 | — | — |
Jul 29, 2026 12w ago | 3 | $28.05 | awaiting T+20 | — | — |
Jul 21, 2026 14w ago | 8-K | $0.8927 | awaiting T+20 | — | — |
Jul 14, 2026 15w ago | 425 / 8-K | $0.7110 | awaiting T+20 | — | — |
Jul 10, 2026 15w ago | 425 / 8-K | $0.6376 | awaiting T+20 | — | — |
Jun 17, 2026 18w ago | EFFECT | $0.6311 $0.7675 | ▲ +21.61% | ▲ +20.30% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers